newsfilter
← Latest News
GlobeNewswire·

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary endpoint 20-patient study suggests combination thera